Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple frailty quiz may help predict chemo risks for seniors with stomach or bowel cancer

NCT ID NCT07184047

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutrition, and muscle health over time. The goal is to help doctors tailor treatment to reduce harm in older, more vulnerable patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which older patients are more likely to have severe side effects from chemotherapy, allowing for more personalized treatment plans.
What could go wrong
This is a small, single-center observational study, not a treatment trial. The results may not apply to all patients or settings, and the frailty scales may not be accurate enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

72 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of at least 72 older patients (≥65 years) with non-metastatic or locally advanced gastrointestinal cancers who are scheduled to receive standard adjuvant chemotherapy at Ankara Etlik City Hospital, Department of Medical Oncology. Patients will be assessed for frailty, sarcopenia, nutritional status, functional independence, and performance status at baseline, 3 months, and 6 months during chemotherapy.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥65 years * Histologically confirmed non-metastatic or locally advanced gastrointestinal cancers (esophageal, gastric, colorectal, pancreatic, biliary tract) * Planned to receive adjuvant chemotherapy (standard regimens such as FOLFOX, CAPEOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, capecitabine, gemcitabine, 5-FU/leucovorin, or oxaliplatin-based regimens) * ECOG Performance Status 0-2 * Ability to complete frailty and functional assessment questionnaires (G8, VES-13, SARC-F, MNA-SF, Katz ADL, Lawton-Brody IADL) * Signed informed consent Exclusion Criteria: * ECOG Performance Status ≥3 * Patients planned for neoadjuvant chemotherapy or chemoradiotherapy * Prior systemic chemotherapy or radiotherapy for the same cancer diagnosis * Severe cognitive impairment preventing questionnaire completion * Patients with advanced frailty at baseline screening * Concurrent enrollment in another interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms chemotherapy-induced toxicity colorectal cancer colorectal neoplasm digestive system cancer digestive system neoplasm esophageal cancer Esophageal Neoplasms Frailty gastric cancer gastric neoplasm malignant pancreatic neoplasm Malnutrition nutritional deficiency disease sarcoglycanopathy Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer Colorectal cancer Esophageal cancer (ESC) Frailty Gastric cancer (GC) Gastrointestinal cancers Malnutrition elderly Older adults (65 years and older) Pancreatic cancer resectable Sarcopenia in elderly Toxicity due to chemotherapy

Contacts and locations

Locations

  • Etlik City Hospital, Medical Oncology Department

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.